» Articles » PMID: 34716900

Harnessing Nanomedicine for Enhanced Immunotherapy for Breast Cancer Brain Metastases

Overview
Publisher Springer
Specialty Pharmacology
Date 2021 Oct 30
PMID 34716900
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Brain metastases (BMs) are the most common type of brain tumor, and the incidence among breast cancer (BC) patients has been steadily increasing over the past two decades. Indeed, ~ 30% of all patients with metastatic BC will develop BMs, and due to few effective treatments, many will succumb to the disease within a year. Historically, patients with BMs have been largely excluded from clinical trials investigating systemic therapies including immunotherapies (ITs) due to limited brain penetration of systemically administered drugs combined with previous assumptions that BMs are poorly immunogenic. It is now understood that the central nervous system (CNS) is an immunologically distinct site and there is increasing evidence that enhancing immune responses to BCBMs will improve patient outcomes and the efficacy of current treatment regimens. Progress in IT for BCBMs, however, has been slow due to several intrinsic limitations to drug delivery within the brain, substantial safety concerns, and few known targets for BCBM IT. Emerging studies demonstrate that nanomedicine may be a powerful approach to overcome such limitations, and has the potential to greatly improve IT strategies for BMs specifically. This review summarizes the evidence for IT as an effective strategy for BCBM treatment and focuses on the nanotherapeutic strategies currently being explored for BCBMs including targeting the blood-brain/tumor barrier (BBB/BTB), tumor cells, and tumor-supporting immune cells for concentrated drug release within BCBMs, as well as use of nanoparticles (NPs) for delivering immunomodulatory agents, for inducing immunogenic cell death, or for potentiating anti-tumor T cell responses.

Citing Articles

Breaking boundaries: role of the brain barriers in metastatic process.

Izadi N, Solar P, Hasanova K, Zamani A, Akbar M, Mrazova K Fluids Barriers CNS. 2025; 22(1):3.

PMID: 39780275 PMC: 11708195. DOI: 10.1186/s12987-025-00618-z.


Metastatic brain tumors: from development to cutting-edge treatment.

Tanzhu G, Chen L, Ning J, Xue W, Wang C, Xiao G MedComm (2020). 2024; 6(1):e70020.

PMID: 39712454 PMC: 11661909. DOI: 10.1002/mco2.70020.


Applications of Nanomedicine in Brain Tumor Therapy: Nanocarrierbased Drug Delivery Platforms, Challenges, and Perspectives.

Verma R, Rao L, Kumar H, Bansal N, Deep A, Parashar J Recent Pat Nanotechnol. 2023; 19(1):99-119.

PMID: 37937554 DOI: 10.2174/0118722105244482231017102857.


Nanomaterials with dual immunomodulatory functions for synergistic therapy of breast cancer brain metastases.

Zhao Z, Li C, Zhang Y, Li C, Chu Y, Li X Bioact Mater. 2023; 27:474-487.

PMID: 37159612 PMC: 10163467. DOI: 10.1016/j.bioactmat.2023.04.021.


Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis.

Wu S, Liu Y, Zhou J, You Y, Zhou X, Chen L Front Oncol. 2023; 13:1091249.

PMID: 37091185 PMC: 10113486. DOI: 10.3389/fonc.2023.1091249.


References
1.
Nussbaum E, Djalilian H, Cho K, Hall W . Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996; 78(8):1781-8. View

2.
Gavrilovic I, Posner J . Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005; 75(1):5-14. DOI: 10.1007/s11060-004-8093-6. View

3.
Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B . Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016; 127(3):407-14. DOI: 10.1007/s11060-016-2075-3. View

4.
Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H . Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. 2016; 18(1):8. PMC: 4717619. DOI: 10.1186/s13058-015-0665-1. View

5.
Mounsey L, Deal A, Keith K, Benbow J, Shachar S, Zagar T . Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. Clin Breast Cancer. 2017; 18(1):29-37. DOI: 10.1016/j.clbc.2017.07.017. View